Investment Analysts’ Recent Ratings Updates for SAB Biotherapeutics (SABS)
Brokerage firms recently updated SAB Biotherapeutics (NASDAQ: SABS) ratings and targets. Citigroup and Jefferies initiated coverage with “buy” ratings and $11 price targets (5/20–5/22/2026). HC Wainwright raised its target to $10 and kept “buy” (5/12). Rodman & Renshaw reaffirmed “buy” with a $13 target (4/2 and 5/11). Zacks upgraded to “hold” (5/11); Weiss reaffirmed “sell (d+)” (4/10).
How this was made
The 30-second read
Why it matters
The primary actionable signal here is sell-side sentiment/valuation framing (initiations, upgrades, and target raises). Traders may use this as a short-term sentiment tailwind, but should not treat it as equivalent to new efficacy/safety or financing news.
Market read
Net effect is a more constructive analyst backdrop for SABS via multiple “buy” notes and higher targets, with some conflicting views (e.g., Zacks “hold”).
What to watch
The article doesn’t provide any trial readout, enrollment update, cash/runway change, or regulatory milestone—so the fundamental driver behind the rating changes is unclear.
Background
SAB Biotherapeutics is a clinical-stage biotech developing fully human polyclonal antibody therapeutics using its Tc Bovine® platform, with lead programs focused on infectious diseases.
Ticker impact
Multiple brokerages updated SAB Biotherapeutics coverage with new/raised price targets and rating changes over the past weeks.
Near-term bias to support the stock on analyst-target momentum, though magnitude depends on whether the market already priced these notes.
The article lists several rating/target updates (Citi, Jefferies, HC Wainwright, Rodman & Renshaw) plus a Zacks upgrade and a prior Weiss “sell (d+)” reaffirmation, implying mixed but net-improving sell-side tone.
Market effects
For clinical-stage biotech, repeated analyst target increases can reinforce risk-on positioning in antibody/platform stories, even without new trial datapoints.
Limited; coverage updates are US-focused and not tied to a specific region-specific catalyst.
Low; no deal, regulatory action, or trial result is described.
Counterpoint
Analyst rating churn without new clinical/financial catalysts may have limited durability; targets can be revised quickly as trial timelines change.
Key entities
- companySAB Biotherapeutics
Clinical-stage biotech; multiple brokerages updated ratings and price targets in the past few weeks.
